Search Results - "Xiong, Julia"

Operationalization, measurement, and health indicators of sedentary behavior in individuals with cerebral palsy: a scoping review by Xiong, Julia (Shi-Peng), Reedman, Sarah E., Kho, Michelle E., Timmons, Brian W., Verschuren, Olaf, Gorter, Jan Willem

“…To explore the operationalization and measurement of sedentary behavior (SB) in individuals with cerebral palsy (CP). We searched five databases from 2011 to…”
Get full text

Comparison of dietary and physical activity behaviors in women with and without polycystic ovary syndrome: a systematic review and meta-analysis of 39 471 women by Kazemi, Maryam, Kim, Joy Y, Wan, Cynthia, Xiong, Julia D, Michalak, Julia, Xavier, Isabella B, Ganga, Kiran, Tay, Chau Thien, Grieger, Jessica A, Parry, Stephen A, Moran, Lisa J, Lujan, Marla E

“…Lifestyle (dietary and/or physical activity [PA]) modification is recommended as first-line therapy to manage polycystic ovary syndrome (PCOS). Current…”
Get full text

Durability of Ultem 9085 in Marine Environments: A Consideration in Fused Filament Fabrication of Structural Components by Wang, Xiong Julia, Travis, Carly, Sorna, Mark T, Arola, Dwayne

“…The long-term durability of polymer components produced by additive manufacturing (AM) in marine conditions is poorly understood. Here, fused filament…”
Get full text

Comprehensive evaluation of disparities in cardiometabolic and reproductive risk between Hispanic and White women with polycystic ovary syndrome in the United States: a systematic review and meta-analysis by Kazemi, Maryam, Kim, Joy Y., Wan, Cynthia, Xiong, Julia D., Parry, Stephen A., Azziz, Ricardo, Lujan, Marla E.

“…We conducted a systematic review and meta-analysis to comprehensively compare cardiometabolic and reproductive health risk between Hispanic and White women…”
Get full text

Valve-sparing root replacement after the Ross procedure by Hobbs, Reilly D., Schultz, Megan L., Loney, Megan L., Verma, Sonaal, Xiong, Julia, Ohye, Richard G., Bove, Edward, Si, Ming-Sing

“…The Ross procedure is a preferred treatment for infants and children with aortic valve disease. Progressive neoaortic root dilation and neoaortic insufficiency…”
Get full text

Regional subgroup analysis of the phase 3 TOPAZ-1 study of durvalumab (D) plus gemcitabine and cisplatin (GC) in advanced biliary tract cancer (BTC) by Vogel, Arndt, Chen, Li-Tzong, He, Aiwu Ruth, Kim, Jin Won, Chen, Ming-Huang, McNamara, Mairead Geraldine, Shimizu, Satoshi, Gillmore, Roopinder, Rey, Felipe, Kim, Hyosung, Xiong, Julia, Makowsky, Mallory, Rokutanda, Nana, Cohen, Gordon, Oh, Do-Youn

“…4075 Background: TOPAZ-1 (NCT03875235) is a randomized, double-blind, global, Phase 3 study evaluating the efficacy and safety of D + GC as first-line…”
Get full text

Patient-reported outcomes for the phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer by Burris III, Howard A., Okusaka, Takuji, Vogel, Arndt, Lee, Myung Ah, Takahashi, Hidenori, Breder, Valeriy Vladimirovich, Blanc, Jean-Frédéric, Li, Junhe, Watras, Magdalena, Xiong, Julia, Abraham, Jayne, Patel, Nikunj, Wang, Julie, Rokutanda, Nana, Cohen, Gordon, Oh, Do-Youn

“…4070 Background: TOPAZ-1 (NCT03875235) is a randomized, double-blind, global, Phase 3 study evaluating the efficacy and safety of durvalumab (D) in combination…”
Get full text

Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial by Loeb, David M., Lee, Ji Won, Morgenstern, Daniel A., Samson, Yvan, Uyttebroeck, Anne, Lyu, Chuhl Joo, Van Damme, An, Nysom, Karsten, Macy, Margaret E., Zorzi, Alexandra P., Xiong, Julia, Pollert, Petra, Joerg, Ingrid, Vugmeyster, Yulia, Ruisi, Mary, Kang, Hyoung Jin

“…Background We report dose-escalation results from an open-label, phase 1/2 trial evaluating avelumab (anti-PD-L1) in paediatric patients with…”
Get full text

A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1 by Oh, Do-Youn, He, Aiwu Ruth, Qin, Shukui, Chen, Li-Tzong, Okusaka, Takuji, Vogel, Arndt, Kim, Jin Won, Suksombooncharoen, Thatthan, Lee, Myung Ah, Kitano, Masayuki, Burris III, Howard A., Bouattour, Mohamed, Tanasanvimon, Suebpong, Zaucha, Renata, Avallone, Antonio, Cundom, Juan, Rokutanda, Nana, Xiong, Julia, Cohen, Gordon, Valle, Juan W.

“…Abstract only 378 Background: BTC is a rare, heterogenous cancer with poor prognosis. Reports on immunogenic features of BTC suggest checkpoint inhibition may…”
Get full text

PMON220 Women With Polycystic Ovary Syndrome Have Worse Lifestyle Behaviors Compared to Controls: A Systematic Review and Meta-Analysis of 36,360 Women by Ganga, Kiran, Grieger, Jessica, Lujan, Marla, Michalak, Julia, Moran, Lisa, Parry, Stephen, Tay, Chau Thien, Wan, Cynthia, Xavier, Isabella, Xiong, Julia, Kazemi, Maryam, Kim, Joy

“…Abstract Women with polycystic ovary syndrome (PCOS) exhibit a propensity for obesity and weight gain during their reproductive years. Accordingly, lifestyle…”
Get full text

Abstract CT236: INTERLINK-1: A phase 3, randomized, double-blind, placebo-controlled, multicenter, global study of monalizumab in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma previously treated with an immune checkpoint inhibitor by Fayette, Jérôme, Seiwert, Tanguy, Ferris, Robert L., Harrington, Kevin, Haddad, Robert, Tahara, Makoto, Licitra, Lisa, Siu, Lillian L., Machiels, Jean-Pascal, Dominiewska, Malgorzata, Xiong, Julia, Kaur, Paramjit, Ruscica, Dario, Cohen, Roger B.

“…Abstract Background: Head and neck (HN) cancer is the 7th most common cancer and 7th leading cause of cancer death worldwide with approximately 930,000 new…”
Get full text

Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751 by Innocenti, Federico, Ramírez, Jacqueline, Obel, Jennifer, Xiong, Julia, Mirkov, Snezana, Chiu, Yi-Lin, Katz, David A, Carr, Robert A, Zhang, Wei, Das, Soma, Adjei, Araba, Moyer, Ann M, Chen, Pei Xian, Krivoshik, Andrew, Medina, Diane, Gordon, Gary B, Ratain, Mark J, Sahelijo, Leonardo, Weinshilboum, Richard M, Fleming, Gini F, Bhathena, Anahita

“…OBJECTIVEABT-751, a novel orally available antitubulin agent, is mainly eliminated as inactive glucuronide (ABT-751G) and sulfate (ABT-751S) conjugates. We…”
Get full text